LXRX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -2301.55%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.88, signalling upside risk potential of 105.71%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 59.86%. Given that Lexicon Pharmaceuticals, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Lexicon Pharmaceuticals, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc. has a beta of 0.963, which suggesting that the stock is 3.666% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 7.16x versus 46.70x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -12425.36%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.88, signalling upside risk potential of 105.71%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Lexicon Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc. has a beta of 0.963, which suggesting that the stock is 3.666% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 7.16x versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CervoMed, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of -2395.1%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat CervoMed, Inc.'s return on equity of -71.5%.

Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.88, signalling upside risk potential of 105.71%. On the other hand CervoMed, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 158.1%. Given that CervoMed, Inc. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe CervoMed, Inc. is more attractive than Lexicon Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc. has a beta of 0.963, which suggesting that the stock is 3.666% less volatile than S&P 500. In comparison CervoMed, Inc. has a beta of -0.910, suggesting its less volatile than the S&P 500 by 191.03%.

Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CervoMed, Inc. pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are larger than CervoMed, Inc. quarterly revenues of $322.6K. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than CervoMed, Inc.'s net income of -$7.7M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CervoMed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 7.16x versus 12.45x for CervoMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -90.04% compared to Lexicon Pharmaceuticals, Inc.'s net margin of 13.19%. Lexicon Pharmaceuticals, Inc.'s return on equity of -49.19% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Lexicon Pharmaceuticals, Inc. has a consensus price target of $2.88, signalling upside risk potential of 105.71%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Lexicon Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Lexicon Pharmaceuticals, Inc..

Lexicon Pharmaceuticals, Inc. has a beta of 0.963, which suggesting that the stock is 3.666% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Lexicon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals, Inc. quarterly revenues are $14.2M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Lexicon Pharmaceuticals, Inc.'s net income of -$12.8M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Lexicon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals, Inc. is 7.16x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.